JP2005535650A - タキキニンアンタゴニストおよびセロトニン再取り込み阻害剤としての置換４−フェニル−ピペリジン−アミド - Google Patents

タキキニンアンタゴニストおよびセロトニン再取り込み阻害剤としての置換４−フェニル−ピペリジン−アミド Download PDF

Info

Publication number
JP2005535650A
JP2005535650A JP2004518696A JP2004518696A JP2005535650A JP 2005535650 A JP2005535650 A JP 2005535650A JP 2004518696 A JP2004518696 A JP 2004518696A JP 2004518696 A JP2004518696 A JP 2004518696A JP 2005535650 A JP2005535650 A JP 2005535650A
Authority
JP
Japan
Prior art keywords
methyl
phenyl
fluoro
ethyl
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004518696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535650A5 (enExample
Inventor
ジュゼッペ・アルヴァロ
フランチェスカ・カルドゥッロ
ロマーノ・ディ・ファビオ
リッカルド・ジョヴァンニ
エリサベッタ・ピガ
マリア・エルヴィラ・トランクィリーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0215393A external-priority patent/GB0215393D0/en
Priority claimed from GB0306454A external-priority patent/GB0306454D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005535650A publication Critical patent/JP2005535650A/ja
Publication of JP2005535650A5 publication Critical patent/JP2005535650A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2004518696A 2002-07-03 2003-07-02 タキキニンアンタゴニストおよびセロトニン再取り込み阻害剤としての置換４−フェニル−ピペリジン−アミド Pending JP2005535650A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0215393A GB0215393D0 (en) 2002-07-03 2002-07-03 Chemical compounds
GB0306454A GB0306454D0 (en) 2003-03-20 2003-03-20 Chemical compounds
PCT/EP2003/007127 WO2004005256A2 (en) 2002-07-03 2003-07-02 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors

Publications (2)

Publication Number Publication Date
JP2005535650A true JP2005535650A (ja) 2005-11-24
JP2005535650A5 JP2005535650A5 (enExample) 2006-08-10

Family

ID=30117089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004518696A Pending JP2005535650A (ja) 2002-07-03 2003-07-02 タキキニンアンタゴニストおよびセロトニン再取り込み阻害剤としての置換４−フェニル−ピペリジン−アミド

Country Status (7)

Country Link
US (1) US20060128752A1 (enExample)
EP (1) EP1558577B1 (enExample)
JP (1) JP2005535650A (enExample)
AT (1) ATE453621T1 (enExample)
AU (1) AU2003257433A1 (enExample)
DE (1) DE60330794D1 (enExample)
WO (1) WO2004005256A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525975A (ja) * 2003-05-09 2006-11-16 グラクソ　グループ　リミテッド 環状アミン誘導体、その製法、およびそれを含有する医薬組成物
WO2012173214A1 (ja) * 2011-06-15 2012-12-20 武田薬品工業株式会社 アゼパン化合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US7276631B2 (en) 2004-07-20 2007-10-02 Bristol-Myers Squibb Company Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists
US7494986B2 (en) 2004-07-20 2009-02-24 Bristol-Myers Squibb Company Cycloalkylamine derivatives as NK-1/SSRI antagonists
US7138423B2 (en) 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
US7098203B2 (en) 2004-07-20 2006-08-29 Bristol-Myers Squibb Company Homopiperidine derivatives as NK-1 antagonists
US7179926B2 (en) 2004-07-26 2007-02-20 Bristol-Myers Squibb Company Aryloxyalkylamine NK-1/SSRI inhibitors
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
CN106278924B (zh) * 2016-06-08 2018-08-17 长沙理工大学 一种以取代米氏酸为酰化剂水相中制备n-芳基叔酰胺的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526761A (ja) * 2001-04-12 2004-09-02 ファーマコピア， インコーポレイテッド Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087209A (en) * 1959-07-13 1963-04-30 Foremost Dairies Inc Container sterilizing apparatus
NL130088C (enExample) * 1960-03-14
US3097029A (en) * 1961-07-07 1963-07-09 Whirlpool Co Broiler drawer door
GB1356118A (en) * 1970-12-16 1974-06-12 Searle & Co 1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid derivatives
JPH08504435A (ja) * 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
MXPA00011204A (es) * 1998-05-15 2003-04-22 Aventis Pharma Inc Derivados de carboxiamida sustituidos con carboxi, como antagonistas de receptor de taquiquinina.
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
FR2784377B3 (fr) * 1998-10-09 2000-11-17 Sanofi Sa Nouveaux composes derives d'ureidopiperidine, antagonistes selectifs des recepteurs nk3 humains, procede pour leur obtention et compositions pharmaceutiques les contenant
NZ531679A (en) * 2001-10-15 2005-02-25 Janssen Pharmaceutica Nv Novel substituted 4-phenyl-4-[1H-imidazol-2-YL]-piperidine derivatives and their use as selective non-peptide delta opioid agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526761A (ja) * 2001-04-12 2004-09-02 ファーマコピア， インコーポレイテッド Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525975A (ja) * 2003-05-09 2006-11-16 グラクソ　グループ　リミテッド 環状アミン誘導体、その製法、およびそれを含有する医薬組成物
WO2012173214A1 (ja) * 2011-06-15 2012-12-20 武田薬品工業株式会社 アゼパン化合物

Also Published As

Publication number Publication date
EP1558577A2 (en) 2005-08-03
DE60330794D1 (de) 2010-02-11
WO2004005256A2 (en) 2004-01-15
EP1558577B1 (en) 2009-12-30
AU2003257433A8 (en) 2004-01-23
AU2003257433A1 (en) 2004-01-23
US20060128752A1 (en) 2006-06-15
WO2004005256A3 (en) 2004-10-14
ATE453621T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
AU2005204234B2 (en) Chemical Compounds
ES2304660T3 (es) Composicion que comprende un antagonista del receptor de taquiquinina y un inhibidor selectivo de la recaptacion de serotonina.
US7276509B2 (en) Piperidine derivatives and their use as antagonists of tachykinins
JP2005535650A (ja) タキキニンアンタゴニストおよびセロトニン再取り込み阻害剤としての置換４−フェニル−ピペリジン−アミド
US7214680B2 (en) 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
US20090192194A1 (en) Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them
US20060058348A1 (en) N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors
US20070135414A1 (en) Tachykinin Antagonists
US7482365B2 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
ES2310295T3 (es) Beta-lactamas para el tratamiento de trastornos del snc.
JP2004525177A (ja) タキキニンアンタゴニストとしてのピペラジン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100511